跳到正文
Science Advances· Yuanding Liu, Zhaofeng Luo, Yuan Gao, Tao Pan, Changjie Yang, Zheng Zhang, Die Yu, Yifan He, Daiquan Chen, Sainan Guo, Yingbin Liu, Yang Sun, Weihong Tan·· 7 天前AI 评分53

靶向 TROP2 的适配体在胰腺癌中实现选择性递药与抗肿瘤活性

A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer

AI 导读

一项发表于 Science Advances 的研究报道了靶向 TROP2 的适配体,可在胰腺癌中实现选择性药物递送并表现较强的抗肿瘤活性。材料仅提供论文标题与卷期信息,未给出适配体序列、载荷类型、动物模型或疗效数据。

原文摘要

出版方登记 · Crossref

Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, highlighting the need for strategies that selectively deliver cytotoxic agents to tumor cells. Trophoblast cell-surface antigen 2 (TROP2) has been proposed as a candidate therapeutic target in PDAC, but non-antibody-based delivery formats remain underexplored. Using protein-SELEX, we identified T17, a high-affinity aptamer that specifically binds to TROP2, and conjugated it to monomethyl auristatin E through an MC-Val-Cit-PAB linker to generate the aptamer-drug conjugate T17-M. Preclinical evaluation in cellular and animal models showed that T17-M retained TROP2-dependent binding, underwent clathrin-mediated internalization and lysosomal processing, and suppressed tumor growth in cell-line-derived and patient-derived xenografts. T17-M also reduced liver metastasis and induced calreticulin exposure, ATP release, and HMGB1 secretion, consistent with immunogenic cell death. In immunocompetent models, T17-M promoted dendritic-cell activation and CD8 + T cell infiltration, while its combination with PD-1 blockade further enhanced tumor control and prolonged survival. These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.

页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文

来源:Science Advances · science.org